Christy Evans
Adult Health · Florence, SCNPI 1336560903
Payments from drug & device makers
Across 161 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$401
- Lilly USA, LLC$395
- Abbott$302
- Merz North America, Inc.$278
- Boehringer Ingelheim$275
- Dexcom, Inc.$248
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,358100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 13 | $401 |
| Lilly USA, LLC | 28 | $395 |
| Abbott | 14 | $302 |
| Merz North America, Inc. | 4 | $278 |
| Boehringer Ingelheim | 15 | $275 |
| Dexcom, Inc. | 12 | $248 |
| Xeris Pharmaceuticals, Inc. | 14 | $240 |
| Cequr Corporation | 4 | $212 |
| Novo Nordisk | 11 | $169 |
| BETA Bionics, Inc. | 7 | $161 |
| AbbVie | 9 | $148 |
| Corcept Therapeutics | 4 | $73 |
| Tandem Diabetes Care, Inc. | 3 | $59 |
| Nevro Corp. | 3 | $55 |
| Bayer | 3 | $52 |
| Amgen | 3 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Merck | 2 | $35 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Zealand Pharma US, Inc. | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Intra-sana Laboratories | 1 | $16 |
| GSK | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,358 in reported general payments places this provider in the 75th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,201 | $1,439,738 |
| JardianceEmpagliflozin | 574 | $571,563 |
| MounjaroTirzepatide | 279 | $338,177 |
| Tresiba Flextouch U-100Insulin Degludec | 405 | $230,658 |
| Tresiba Flextouch U-200Insulin Degludec | 219 | $189,962 |
| FarxigaDapagliflozin Propanediol | 163 | $169,063 |
| TrulicityDulaglutide | 99 | $122,292 |
| Humalog Kwikpen U-200Insulin Lispro | 82 | $95,126 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $69,136 |
| TradjentaLinagliptin | 90 | $65,401 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 57 | $57,709 |
| Novolog FlexpenInsulin Aspart | 221 | $46,019 |
| RybelsusSemaglutide | 23 | $42,419 |
| Humalog Kwikpen U-100Insulin Lispro | 201 | $41,142 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $36,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $169 | $1,495,9831,260 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $275 | $648,295681 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30 | $395 | $467,519412 claims |
| AstraZenecaFarxiga | $14 | $169,063163 claims |
| MerckJanuvia, Janumet Xr, Janumet | $35 | $68,45670 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 292 adult health providers in South Carolina.
Other adult health in Florence
- Jamie ShorterFlorence$7K
- Karen RobertsonGreenville$69K
- Christine FranzeseTega Cay$30K
- Jessica RiceGreenville$15K
- Michelle PriceCharleston$13K
- Melissa McCarterSpartanburg$12K
- Andrea OlsonWest Columbia$12K
- Jennifer BrittIrmo$11K
- Nichole SnowSpartanburg$10K
- Christi WigginsWest Columbia$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.